Abstract
It has been repeatedly described that plasma or CSF tryptophan concentrations increase in experimental animal models of liver impairment and in patients suffering from hepatic encephalopathy or hepatic coma (Hirayama, 1971; Curzon et al. 1973; Sourkes, 1978; ONO et al. 1996). It has also been demonstrated that the administration of large doses of tryptophan to patients affected by hepatic disorders or to dogs with a portocaval shunt may lead to coma (Sherlock, 1975; Rossi-Fanelli et al. 1982). On the basis of the widely agreed assumption that increased brain tryptophan concentrations signify increased 50Htryptamine turnover, several years ago, a number of investigators proposed that an increased stimulation of 50H-tryptamine receptors plays a key role in the neurological and psychiatric symptoms associated with liver diseases (Cummings et al. 1976). Tryptophan may be metabolized not only into 50H-tryptamine, but also into quinolinic or kynurenic acids, neuroactive compounds which are able to interact with glutamate receptors of the NMDA type (see: Stone, 1993 for a review). Approximately ten years ago, we observed that quinolinic acid was indeed increased in the rat brain with portocaval anastomosis or in patients who had died in hepatic coma (Moroni et al. 1986; Moroni et al. 1986a). We therefore proposed that “..quinolinic acid should be added to the list of compounds possibly involved in the pathogenesis and symptomatology of brain disorders associated to liver failure.” Other groups have recently confirmed that quinolinic acid is indeed increased in the blood and brain of rat models suffering from either acute or chronic liver failure. The concentration of quinolinic acid in the brain, however, does not seem to correlate with the neurological symptoms observed in these liver disorders. Furthermore, it is possible that quinolinic acid synthesis occurs mostly in macrophages or other periphalopathy may be “minor” (Bergquist et al. 1995; Basile et al. 1995).
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Basile, A.S., L. Panell, T. Jaouni, S.H. Gammal, H. Fales, E.A. Jones and P. Skolnick, 1990, Brain concentration of benzodiazepines are elevated in an animal model of hepatic encephalopathy, Proc. Natl. Acad. Sci. USA 97, 5263.
Basile, A.S., K. Saito, H. Li and M.P. Heyes, 1995, The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy in animal models of fulminant hepatic failure, J. Neurochem. 64, 2607.
Basile, A.S., E.A. Jones and P. Skolnick, 1991, The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands, Pharmacol. Rev. 42, 27.
Bergquist, P.B.F., M.P. Heyes, M. Bugge and F. Bengtsson, 1995, Brain quinolinic acid in chronic hepatic encephalopathy, J. Neurochem. 65, 2235.
Carpenedo, R., A. Chiarugi, P. Russi, G. Lombardi, V. Carlà, R. Pellicciari, L. Mattoli and F. Moroni, 1994, Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenic acid and have sedative and anticonvulsant activities, Neuroscience 61, 237.
Chiarugi, A., R. Carpenedo, M.T. Molina, L. Mattoli, R. Pellicciari and F. Moroni, 1995, Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem. 65, 1176–1183.
Chiarugi, A., R. Carpenedo and F. Moroni, 1996, Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase, J. Neurochem. 67, 692.
Cummings, M.G., H.J. James and P.B. Soeters, 1976, Regional brain studies of indoleamine metabolism in the rat in acute hepatic failure, J. Neurochem. 27, 741.
Curzon, G., B.D. Kantamaneni, J. Winch, A. Rojas-Bueno, I.M. Murray-Lyon and R. Williams, 1973, Plasma and brain tryptophan changes in experimental acute hepatic failure, J. Neurochem. 21, 137.
Fraser, C.L. and A.I. Arieff, 1985, Hepatic encephalopathy, N. Engl. J. Med. 313, 865.
Hirayama, C. 1971, Tryptophan metabolism in liver disease, Clin. Chim. Acta 32, 191.
Jones, E.A., D.E. Shafer, P. Ferenci and S.C. Pappas, 1984, The neurobiology of hepatic encephalopathy, Hepatology 4, 1235.
Jones, E.A., C. Yurdaydin, A.S. Basile, J.E. Maddison, W.E. Watson, G.A. Johnston, C.H. Dejong, N.E. Deutz, P.B. Soeters, V. Felipo, E. Grau, M.D. Minana, S. Grisolia, K.D. Mullen, Z.Q. Gu, G. Nowak, C. Fromm, A.G. Holt, D.B. Jones, A. Puspok, A. Herneth, P. Steindl, P. Ferenci, S. Sarhan, B. Knodgen, C. Grauffel, N. Seiler and S. Sherlock, 1993, The GABA hypothesis--state of the art Glutamatergic neurotransmission in hepatic encephalopathy, Adv. Intern. Med. 38, 245.
King, L.J., D.V. Parke and R.T. Williams, 1966, The metabolism of [2-14C]indole in the rat, Biochem. J. 98, 266.
Kooyman, R.A., J.A. van Hooft, P.M.L. Vanderheij den and H.P.M. Vijverberg, 1994, Competitive and non-competitive effects of 5-hydroxyndole on 5HT3 receptors in N 1 E115 neurpblastoma cells, Br. J. Pharmacol. 112, 541.
Kooyman, R.A., J.A. van Hooft and H.P.M. Vijverberg, 1993, 5-Hydroxyindole slows desensitization of the 5HT3 receptor-mediated ion current in N1E-115 neuroblastoma cells, Br. J Pharmacol. 108, 287.
Lombardi, G., G. Mannaioni, P. Leonardi, G. Cherici, V. Carlà and F. Moroni, 1994, Ammonium acetate inhibits ionotropic receptors and differentially affects metabotropic receptors for glutamate, J. Neural Transm. 97, 187.
Mannaioni, G., M. Alesiani, V. Carlà, B. Natalini, M. Marinozzi, R. Pellicciari and F. Moroni, 1994, Sulfate esters of hydroxy amino acids as stereospecific glutamate receptor agonists, Eur. J. Pharmacol. 251, 201.
Moroni, F., G. Lombardi, V. Carlà and G. Moneti, 1984, The excitotoxin quinolinic acid is present and unevenly distributed in the rat brain, Brain Res. 295, 352.
Moroni, F., G. Lombardi, V. Carlà, S. Lal, P.E. Etienne and N.P.V. Nair, 1986a, Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure, J. Neurochem. 47, 1667.
Moroni, F., G. Lombardi, V. Carlà, D. Pellegrini, G.L. Carassale and C. Cortesini, 1986b, Content of quinolinic acid and of other tryptophan metabolites increases in brain regions of rats used as experimental models of hepatic encephalopathy, J. Neurochem. 46, 869.
Moroni, F., O. Riggio, V. Carlà, V. Festuccia, F. Ghinelli, I.R. Marino, M. Merli, L. Natali, G. Pedretti, F. Fiaccadori and L. Capocaccia, 1987, Hepatic Encephalopathy:lack of changes of GABA content in plasma and cerebrospinal fluid, Hepatology 7, 816.
Moroni, F., P. Russi, G. Lombardi, M. Beni and V. Carlà, 1988, Presence of kynurenic acid in the mammalian brain, J Neurochem. 51, 177.
Moroni, F., P. Russi, M.A. Gallo-Mezo, G. Moneti and R. Pellicciari, 1991, Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine, J. Neuróchem. 57, 1630.
Olasmaa, M., A. Guidotti, E. Costa, J.D. Rothstein, M.E.. Goldman, R.J. Weber and S.M. Paul, 1989, Endogenous benzodiazepines in hepatic encephalopathy, Lancet 1, 491.
Ono, J., D.G. Huston, R.S. Dombro, U.E. Levi, A. Livingstone and R. Zeppa, 1996, Tryptophan and hepatic coma, Gastroenterology 74, 196.
Orcutt, J.A., J.P. Prytherch, M. Konicov and S.M. Michaelson, 1964, Some new compounds exhibiting selective CNS-depressant activities. Parti, Preliminary observations, Arch. Int. Pharmacodyn. 152, 121.
Rossi-Fanelli, F., H. Freund, R. Krause, A.R. Smith, H. James, S. Castorina-Ziparo and J.E. Fischer, 1982, Induction of coma in normal dogs by infusion of aromatic amino acids and its prevention by the addition of branched chain amino acids, Gastroenterology 83, 664.
Sherlock, S. 1975, Diseases of the liver and biliary system (Blackwell, Oxford)
Sourkes, T.L. 1978, Tryptophan in hepatic coma, J. Neural Transm. S14, 79.
Stone, T.W. 1993, Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev.45, 309.
Van Pée, K.H. and F. Lingens, 1984, Metabolism of tryptophan in pseudomona aureofaciens, in: Progress in tryptophan and serotonin research,eds. H.G. Schlossberger, W. Kochen, B. Linzen and H. Steinhart (de Gruyter,W. Berlin) p. 753.
Zeneroli, M.D., E. Iuliano, G. Racagni and M. Baraldi, 1982, Metabolism and brain uptake of GABA in galactosamine induced hepatic encephalopathy in rats, J. Neurochem. 38, 1219.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Moroni, F. et al. (1997). Studies on the Pharmacological Properties of Oxindole (2-Hydroxyindole) and 5-Hydroxyindole: Are They Involved in Hepatic Encephalopathy?. In: Felipo, V., Grisolía, S. (eds) Advances in Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy. Advances in Experimental Medicine and Biology, vol 420. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5945-0_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5945-0_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7724-5
Online ISBN: 978-1-4615-5945-0
eBook Packages: Springer Book Archive